Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Advanced Renal Cell Carcinoma (MERITS)
NCT00848640Phase 2Completed
- Sponsor
- Egyptian Foundation for Cancer Research
- Start
- Oct 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in metastatic renal cell carcinoma (mRCC), sponsored by Egyptian Foundation for Cancer Research. Started Oct 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00848640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00848640.